{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:28:15Z","timestamp":1792175295210,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.omtm.2019.01.010","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:15:22Z","timestamp":1548807322000},"page":"205-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":155,"special_numbering":"C","title":["EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation"],"prefix":"10.1016","volume":"13","author":[{"given":"Giulia","family":"Detela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2019.01.010_bib1","first-page":"1","article-title":"Advanced therapy medicinal products: current and future perspectives","volume":"4","author":"Hanna","year":"2016","journal-title":"J.\u00a0Mark. Access Health Policy"},{"key":"10.1016\/j.omtm.2019.01.010_bib2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1089\/humc.2016.193","article-title":"Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?","volume":"28","author":"Bor\u00e1\u0148","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.omtm.2019.01.010_bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fmed.2017.00182","article-title":"Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework","volume":"4","author":"Carvalho","year":"2017","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.omtm.2019.01.010_bib4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.18609\/cgti.2016.056","article-title":"Manufacturing process development of ATMPs within a regulatory framework for EU clinical trial & marketing authorisation applications","volume":"2","author":"Detela","year":"2016","journal-title":"Cell Gene Ther. Insights"},{"key":"10.1016\/j.omtm.2019.01.010_bib5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.15252\/emmm.201607293","article-title":"Patient-driven search for rare disease therapies: the Fondazione Telethon success story and the strategy leading to Strimvelis","volume":"9","author":"Monaco","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2019.01.010_bib9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40272-017-0261-1","article-title":"Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation","volume":"19","author":"Tomasi","year":"2017","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.omtm.2019.01.010_bib14","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0140-6736(96)11188-0","article-title":"Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium","volume":"349","author":"Pellegrini","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2019.01.010_bib15","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1097\/00007890-200111150-00002","article-title":"Autologous fibrin-cultured limbal stem cells permanently restore the corneal surface of patients with total limbal stem cell deficiency","volume":"72","author":"Rama","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.omtm.2019.01.010_bib16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.18609\/cgti.2016.023","article-title":"Holoclar: first of its kind in more ways than one","volume":"2","author":"Milazzo","year":"2016","journal-title":"Cell Gene Ther. Insights"},{"key":"10.1016\/j.omtm.2019.01.010_bib17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/sctm.17-0003","article-title":"Navigating Market Authorisation: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union","volume":"7","author":"Pellegrini","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.omtm.2019.01.010_bib19","doi-asserted-by":"crossref","first-page":"14066","DOI":"10.1038\/mtm.2014.66","article-title":"Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera","volume":"2","author":"Watanabe","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2019.01.010_bib20","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.drudis.2016.06.025","article-title":"Transparency in drug regulation: public assessment reports in Europe and Australia","volume":"21","author":"Papathanasiou","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omtm.2019.01.010_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2217\/rme.14.65","article-title":"Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use","volume":"10","author":"Salmikangas","year":"2015","journal-title":"Regen. Med."},{"key":"10.1016\/j.omtm.2019.01.010_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.18609\/cgti.2015.010","article-title":"Regulatory viewpoints on the development of advanced stem cell\u2013based medicinal products in light of the first EU-approved stem cell product","volume":"1","author":"Flory","year":"2015","journal-title":"Cell Gene Ther. Insights"},{"key":"10.1016\/j.omtm.2019.01.010_bib28","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1177\/0363546514528093","article-title":"Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Two-Year Follow-up of a Prospective Randomized Trial","volume":"42","author":"Saris","year":"2014","journal-title":"Am. J. Sports Med."},{"key":"10.1016\/j.omtm.2019.01.010_bib29","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/0363546518756976","article-title":"Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Five-Year Follow-up of a Prospective Randomized Trial","volume":"46","author":"Brittberg","year":"2018","journal-title":"Am. J. Sports Med."},{"key":"10.1016\/j.omtm.2019.01.010_bib30","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtm.2019.01.010_bib31","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1245\/s10434-018-6361-5","article-title":"Implementing a Program of Talimogene laherparepvec","volume":"25","author":"Collichio","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.omtm.2019.01.010_bib32","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2019.01.010_bib33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2019.01.010_bib34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omtm.2019.01.010_bib35","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","article-title":"Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\u2019s disease: a phase 3 randomised, double-blind controlled trial","volume":"388","author":"Pan\u00e9s","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2019.01.010_bib36","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2017.12.020","article-title":"Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn\u2019s Disease","volume":"154","author":"Pan\u00e9s","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtm.2019.01.010_bib37","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood-2011-12-396879","article-title":"Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency","volume":"120","author":"Hassan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2019.01.010_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13018-017-0570-7","article-title":"Safety of three different product doses in autologous chondrocyte implantation: results of a prospective, randomised, controlled trial","volume":"12","author":"Becher","year":"2017","journal-title":"J.\u00a0Orthop. Surg. Res."},{"key":"10.1016\/j.omtm.2019.01.010_bib39","series-title":"Mesenchymal Stromal Cells: Translational Pathways to Clinical Adoption","first-page":"243","article-title":"Chapter 10: global regulatory perspective for MSCs","author":"Lodge","year":"2017"},{"key":"10.1016\/j.omtm.2019.01.010_bib42","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/jama.2017.15218","article-title":"FDA approval of tisagenlecleucel: Promise and complexities of a $475 000 cancer drug","volume":"318","author":"Bach","year":"2017","journal-title":"JAMA"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119300130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119300130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:26:46Z","timestamp":1762421206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050119300130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":27,"alternative-id":["S2329050119300130"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2019.01.010","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2019.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}